Bronchiectasis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Bronchiectasis Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including Bronchiectasis clinical trials and nonclinical stage products. It also covers the Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Bronchiectasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Bronchiectasis Pipeline Outlook [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from Bronchiectasis Pipeline Report

* In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis.
* In May 2025, Genentech Inc . announced a phase I study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-Obstructive Disease.
* In May 2025, Mannkind Corporation conducted a phase 3 study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection.
* DelveInsight's Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.
* The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A . and others.
* Promising Bronchiectasis Pipeline Therapies such as Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.

Stay ahead with the most recent pipeline outlook for Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bronchiectasis Treatment Drugs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bronchiectasis Emerging Drugs Profile

* Benralizumab: AstraZeneca

Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis.

* S1226: SolAeroMed

S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways.The rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the Ss-adrenergic agonists and thus complements, rather than replaces, existing treatments.

* Brensocatib: Insmed

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.

The Bronchiectasis Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.
* Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market

Explore groundbreaking therapies and clinical trials in the Bronchiectasis Pipeline. Access DelveInsight's detailed report now! @ New Bronchiectasis Drugs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pulmonary Fibrosis Companies

AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A . and others.

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous

Bronchiectasis Products have been categorized under various Molecule types such as

* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine

Unveil the future of Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Bronchiectasis Pipeline Report

* Coverage- Global
* Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A . and others.
* Bronchiectasis Pipeline Therapies- Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
* Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Bronchiectasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Bronchiectasis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Bronchiectasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchiectasis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Benralizumab: AstraZeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* S1226: SolAeroMed
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CSL787: CSL Behring
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AP-PA02: Armata Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Bronchiectasis Key Companies
* Bronchiectasis Key Products
* Bronchiectasis- Unmet Needs
* Bronchiectasis- Market Drivers and Barriers
* Bronchiectasis- Future Perspectives and Conclusion
* Bronchiectasis Analyst Views
* Bronchiectasis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchiectasis-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.